Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHOCARBAMOL vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: Tetanus-associated muscle spasms,Off-label: Postoperative muscle spasms
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life: 1-2 hours. Clinical context: short half-life necessitates frequent dosing (q6h) for sustained muscle relaxation.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Metabolized by the liver via dealkylation and hydroxylation. The major metabolic pathway involves O-dealkylation to form a glycinate conjugate, with CYP450 enzymes likely involved.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal: primarily as glucuronide conjugates and unchanged drug (~50-70% as metabolites, <2% unchanged). Fecal: minimal, <2%. Biliary: not significant.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Protein binding: 46-50% to albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Volume of distribution: 0.6-0.8 L/kg. Clinical meaning: distributes widely into tissues, moderate Vd indicating extravascular distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: high bioavailability, ~80-100% (well absorbed with first-pass metabolism to inactive conjugates). Intravenous: 100%.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Cr Cl <50 m L/min: Administer every 8-12 hours; Cr Cl <30 m L/min: Administer every 12 hours; hemodialysis: Supplementation not well-defined; avoid if possible due to propylene glycol content.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Contraindicated.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not recommended for children under 16 years; safety and efficacy not established.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Start at lower end of dosing range (e.g., 750 mg orally 4 times daily) due to increased risk of sedation and falls; monitor renal function and adjust accordingly.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No FDA black box warning.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
May cause dizziness, drowsiness, or blurred vision; caution with activities requiring mental alertness. Use with caution in patients with hepatic impairment, renal impairment, or myasthenia gravis. Avoid concurrent use with other CNS depressants. May cause urine discoloration (brown, black, or blue).
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to methocarbamol or any component of the formulation; concomitant use of anticholinesterase drugs in patients with myasthenia gravis (contraindicated); known history of G6PD deficiency (relative, due to risk of hemolytic anemia).
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No significant food interactions. Grapefruit juice does not affect methocarbamol. However, avoid alcohol entirely due to additive CNS depression.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities (reduced fetal weight, skeletal ossification delays) at doses 1-3 times human dose; no adequate human studies. Second and third trimesters: Potential for neonatal CNS depression and hypotonia if used near term. Avoid use unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Excreted in breast milk in small amounts; M/P ratio not established. No reported adverse effects in infants. Caution is advised due to potential for CNS depression or muscle weakness.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No established dose adjustment guidelines. Increased renal clearance during pregnancy may reduce serum levels; however, safety data insufficient. Use lowest effective dose for shortest duration.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Methocarbamol is a centrally acting muscle relaxant with sedative properties. Avoid or taper to prevent rebound muscle spasm. Monitor for CNS depression, especially when combined with alcohol or other CNS depressants. Use cautiously in elderly due to fall risk. May cause urine discoloration (brown, black, or blue-green) which is benign. Onset of action is within 30 minutes; maximal effect in 1-2 hours. Typical adult dose: 1.5-2 g PO QID for first 2-3 days, then 1 g QID.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication may cause drowsiness, dizziness, or blurred vision. Do not drive, operate machinery, or perform hazardous tasks until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation and risk of falls.,Notify your healthcare provider if you experience fever, rash, itching, or jaundice (yellowing of skin/eyes).,Urine may turn brown, black, or blue-green; this is harmless and not a cause for alarm.,Do not stop suddenly; gradual dose reduction is recommended to prevent withdrawal symptoms like muscle spasm or anxiety.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"The coadministration of propofol, a GABA-A receptor agonist general anesthetic, with methocarbamol, a centrally acting muscle relaxant, can produce additive sedative and respiratory depressant effects. This interaction may lead to excessive sedation, prolonged recovery from anesthesia, and an increased risk of hypoxia or apnea. Clinically, patients may exhibit deeper levels of unconsciousness and require prolonged monitoring of respiratory function."
"Methocarbamol, a centrally acting muscle relaxant, potentiates the sedative effects of nabilone, a synthetic cannabinoid used for chemotherapy-induced nausea and vomiting. This additive central nervous system depression can lead to excessive drowsiness, dizziness, impaired motor coordination, and increased risk of falls or cognitive impairment. Clinically, patients may experience exacerbated sedation, confusion, and psychomotor slowing, particularly when initiating therapy or at higher doses."
"Concomitant use of methocarbamol and gabapentin enacarbil results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic neurotransmission and neuronal excitability. This synergistic interaction significantly increases the risk of excessive sedation, dizziness, and impaired psychomotor function, potentially leading to falls, cognitive deficits, or respiratory depression in susceptible patients. Clinical outcomes are dose-dependent and more pronounced in elderly patients or those with pre-existing CNS compromise."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHOCARBAMOL vs ACTIQ, answered by our medical review team.
METHOCARBAMOL is a Skeletal Muscle Relaxant that works by Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHOCARBAMOL and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHOCARBAMOL is: METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METHOCARBAMOL and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METHOCARBAMOL is classified as Category A/B. FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities (reduced fetal weight, skeletal ossification delays) at doses 1-3 times human dose; no adequate h. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.